The European Medicines Agency (EMEA) says that French pharmaceutical group Sanofi-Aventis' anti-obesity drug Acomplia (rimonabant) should not be used by patients suffering major depression, or those who are receiving anti-depressant medication, due to the potential risk of psychiatric side effects. The news follows the firm's withdrawal of its US approval application earlier in the month (Marketletter July 9).
The EMEA said that the drug, which has been available as an adjunct to diet and exercise in the treatment of obesity since last summer (Marketletter May 8, 2006), has carried warnings of potential psychiatric side effects since it was launched. The agency added that, having conducted a review of all information on potential side effects provided by Sanofi, it has concluded that, while the drug's benefits continue to outweigh its risks for the majority of users, this was not the case in patients suffering from depression.
The EMEA also said that any patient experiencing depression as a result of taking Acomplia should discontinue treatment, adding that it would be issuing a letter detailing the additional safety information to physicians in due course. Despite the announcement, the firm's share price improved 1% to 62.26 euros in trading on Paris Bourse on July 20.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze